BASF increases prices for pharmaceutical excipients and active ingredients
Advertisement
Effective September 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and generic active pharmaceutical ingredients by 10%.
This price increase affects the entire excipients portfolio including all binders, disintegrants, coatings, solubilizers, and solvents. The affected generic active pharmaceutical ingredient (API) portfolio contains products like Ibuprofen, Caffeine, and Pseudoephedrine.
Due to the continued rise in costs for raw materials, energy and labor this price increase has become necessary. All existing contractual obligations will be honored.
Most read news
Topics
Organizations
Other news from the department price development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Evonik increases prices of cGMP-grade amino acids
BASF increases prices for vitamin B2
Significant overall survival benefit observed with radium 223 in patients with castration-resistant prostate cancer
Revolutionary Pan-Genome Analysis of Lactic Acid Bacteria Unveils Promising Opportunities for Food Industry and Healthcare
Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million
Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
Lonza expands bioconjugation in Visp with two additional manufacturing suites
Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth
Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host
Simtra BioPharma Solutions - Parsippany, USA